2-propenylfuran | 10599-55-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 杂芳族化合物
• 英文名称: 2-propenylfuran
• 英文别名: 2-prop-1-enylfuran
• CAS: 10599-55-0
• 化学式: C₇H₈O
• 分子量: 108.14
• InChiKey: IGWQTPINFQSICW-UHFFFAOYSA-N

物化性质

• 沸点：
  32 °C(Press: 13 Torr)
• 密度：
  0.9450 g/cm3

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  8
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  13.1
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  2-propenylfuran 在 镍 作用下， 生成 4-庚醇
  参考文献：
  名称：

  Schuikin; Bel'skii, Zhurnal Obshchei Khimii, 1956, vol. 26, p. 2716,2717; engl. Ausg. S. 3025, 3026

  摘要：

  DOI：
• 作为产物：
  描述：

  2-furyl 2-methyl oxirane 在 硫脲 作用下， 以 水 为溶剂， 生成 2-propenylfuran
  参考文献：
  名称：

  Bouda, H.; Borredon, M. E.; Delmas, M., Synthetic Communications, 1989, vol. 19, # 3and4, p. 491 - 500

  摘要：

  DOI：

文献信息

• Nickel Catalyzed Cross-Couplingand Amination Reactions of Aryl Nitriles
  作者：Joseph Miller、John Dankwardt、Jonathan Penney

  DOI：10.1055/s-2003-40873

  日期：2003.8

  Aryl nitriles have been found to participate in cross-coupling and amination reactions via nickel-catalyzed activation of the C-CN bond. With the development of these synthetically useful transformations, aryl nitriles can now be considered along with aryl halides and sulfonates as viable substrates for these types of reactions.

  已发现芳腈通过镍催化的 C-CN 键活化参与交叉偶联和胺化反应。随着这些合成有用的转化的发展，现在可以考虑将芳基腈与芳基卤化物和磺酸盐一起作为这些类型反应的可行底物。
• The stereochemistry of rearrangements of aryl and hetaryl groups to primary carbenic centers
  作者：W.E. Slack、W. Taylor、C.G. Moseley、K.T. Chang、A. Kraska、L.H. Press、L. Cherney、H. Shechter

  DOI：10.1016/s0040-4039(00)76996-6

  日期：1994.4

  The products and stereochemistries of carbenic decompositions of varied 2-aryl-1-diazoalkanes and 1-diazo-2-(2-hetaryl)propanes have been determined.

  已经确定了各种2-芳基-1-重氮烷和1-重氮-2-（2-杂芳基）丙烷的羧基分解产物和立体化学。
• Nickel catalyzed cross-coupling of modified alkyl and alkenyl Grignard reagents with aryl- and heteroaryl nitriles: activation of the CCN bond
  作者：Joseph A Miller、John W Dankwardt

  DOI：10.1016/s0040-4039(03)00075-3

  日期：2003.2

  The nickel catalyzed cross-coupling of alkyl and alkenyl Grignard reagents with aryl nitrile derivatives affords good yields of the corresponding aryl alkanes or aryl alkenes via activation of the CCN bond. To prevent direct addition of the nucleophile to the nitrile group, the reactivity of the Grignard reagent was modulated by reaction with either LiOt-Bu or PhSLi prior to cross-coupling. The optimum

  烷基和链烯基格氏试剂与芳基腈衍生物的镍催化交叉偶联可通过CCN键的活化获得相应的芳基烷烃或芳基烯烃的良好收率。为了防止亲核试剂直接加成到腈基上，格利雅试剂的反应性通过在交叉偶联之前与LiO t- Bu或PhSLi反应来调节。确定最佳催化剂为NiCl 2（PMe 3）2，这是一种方便的，空气稳定的可商购的配合物。
• MATRIX METALLOPROTEASE INHIBITORS
  申请人：YANG Shyh-Ming

  公开号：US20080085893A1

  公开（公告）日：2008-04-10

  The present invention relates to compounds of Formula I, wherein R1, R2, R3, R4, R5, R6, and R7 are defined in the specification. In addition, the present invention relates to methods treating disorders related to matrix metalloproteases. More particularly, the compounds of the present invention are useful for treating stroke.

  本发明涉及式I的化合物，其中R1、R2、R3、R4、R5、R6和R7在规范中定义。此外，本发明涉及治疗与基质金属蛋白酶相关疾病的方法。更具体地，本发明的化合物对治疗中风具有用处。
• 2,6-SUBSTITUTED-4-MONOSUBSTITUTEDAMINO-PYRIMIDINE AS PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS
  申请人：Lim Sungtaek

  公开号：US20070244131A1

  公开（公告）日：2007-10-18

  The present invention is directed to a compound of Formula (I) wherein Cy 1 , Cy 2 , L 1 , L 2 , and R 1 are as defined herein, a pharmaceutical composition comprising a pharmaceutically effective amount of one or more compounds according to Formula (I) in admixture with a pharmaceutically acceptable carrier, and a method of treating a patient suffering from a PGD2-mediated disorder including, but not limited to, allergic disease (such as allergic rhinitis, allergic conjunctivitis, atopic dermatitis, bronchial asthma and food allergy), systemic mastocytosis, disorders accompanied by systemic mast cell activation, anaphylaxis shock, bronchoconstriction, bronchitis, urticaria, eczema, diseases accompanied by itch (such as atopic dermatitis and urticaria), diseases (such as cataract, retinal detachment, inflammation, infection and sleeping disorders) which is generated secondarily as a result of behavior accompanied by itch (such as scratching and beating), inflammation, chronic obstructive pulmonary diseases, ischemic reperfusion injury, cerebrovascular accident, chronic rheumatoid arthritis, pleurisy, ulcerative colitis and the like by administering to said patient a pharmaceutically effective amount of a compound according to Formula (I).

  本发明涉及一种式（I）的化合物，其中Cy1，Cy2，L1，L2和R1如本文所定义，一种制药组合物，包括一种或多种按照式（I）的化合物的药物有效量与药学可接受载体的混合物，以及一种治疗患有PGD2介导的疾病的患者的方法，包括但不限于过敏性疾病（如过敏性鼻炎，过敏性结膜炎，特应性皮炎，支气管哮喘和食物过敏），全身性肥大细胞病，伴随全身性肥大细胞激活的疾病，过敏性休克，支气管收缩，支气管炎，荨麻疹，湿疹，伴随瘙痒的疾病（如特应性皮炎和荨麻疹），疾病（如白内障，视网膜脱落，炎症，感染和睡眠障碍），这些疾病是由于伴随瘙痒的行为（如搔抓和敲打）而次生产生的，炎症，慢性阻塞性肺疾病，缺血再灌注损伤，脑血管意外，慢性类风湿性关节炎，胸膜炎，溃疡性结肠炎等，通过向该患者注射按照式（I）的化合物的药物有效量。